Affy Posts Slight Rise in Q3 Revenues, Looks to Expand Share in GWAS Market

Though Affy saw a 12-percent increase in sales of RNA consumables in Q3, such as its gene-expression arrays and Panomics QuantiGene assays, sales of DNA consumables, including whole-genome genotyping SNP arrays, were down 14 percent due to a "temporary slowdown in whole-genome association studies."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.